Upcoming Events
MSQ Ventures reviewed thousands of American/European companies and successfully connected them with our strategic partners and financial investors in China. We hosted many events essential to both the investors and the entrepreneurs, creating a win-win situation.
2021 Cross-Border Healthcare Innovation & Partnership Summit
MSQ Ventures is hosting its 2021 Cross-Border Healthcare Innovation & Partnership Summit, a Virtual event on September 23rd and 24th, together with BayHelix Group. REGISTER HERE
2021 4TH CHINA BIO-PHARMPARTNERING FORUM
MSQ is organizing the 4th China Bio-Pharma Partnering Forum 2021, in Suzhou China on June 25th and 26th. The conference will invite 100+ authoritative leaders and 1000+ industry experts to share the most cutting-edge technical information, interpret the latest industrial policies, and fully link the multi-platform of industry, university, research, and investment.
2021 Future Healthcare VB100 Conference Global Digital Health Innovation Forum
MSQ is co-hosting the 2021 Future Healthcare VB100 Conference Global Digital Health Innovation Forum with VCBeat, on April 16-18th, 2021 in Wujiang District, Suzhou, China. The conference has been successfully held in the past four years with more than 600 global healthcare leaders invited as speakers and more than 1200 VC/PE/Investment banking/corporate ventures attended. More
2021 Cross-Border Healthcare Innovation & Partnership Summit
According to Shanghai Disease Control and Prevention requirements, because of the newly found community-spread COVID-19 cases in Shanghai on Jan 21st, our in-person 2021 Cross-Border Healthcare Innovation & Partnership Summit on Jan 28th has changed to Virtual Summit.
2nd Annual Bio Cross-border Investment & Partnership Summit 2020
MSQ will host its 2nd Annual Bio Cross-border Investment & Partnership Summit 2020, together with CMG-SDIC Capital (State Development & Investment Corporation) and Pharnex in Shanghai, China on Dec 18th, 2020.
Bio-europe 2020 china session
MSQ will host a China Session during the Bio-Europe 2020 (Oct 26 - Oct 29, 2020) on “Cross-Border Deals and Opportunities and Challenges for Assets in Different Clinical Trial Stages to Enter China”, with Panelists: CEO at I-Mab Biopharma Dr. Joan Huaqiong Shen, Venture Partner at Hillhouse Capital Management Ed Zhang, CEO at VistaGen Therapeutics Shawn Singh, and Managing Director at BioBasel Consulting and ChinaBio Capital Dr. Robert Narquizian.
MSQ News
Sept 23 and 24, 2021: 2021 Cross-Border Healthcare Innovation & Partnership Autumn Summit was successfully held virtually by MSQ Ventures and Bayhelix. This summit consisted of 2 panel discussions, 2 expert speeches, and 7 company presentations
Sept 8, 2021: MSQ published 2021 H1China Biopharma Review to summarize China Biopharma companies license in/out deals, IPO, and 2021 H1 highlights, case study, and insights
June 25 and 26, 2021: 4th China Bio-Pharma Partnering Forum 2021 was successfully held in Suzhou, China, by MSQ Ventures and Healife Group. The event attracted more than 1,000 professional delegates. More than 100 business meetings and 100 leading lectures were held.
May 18, 2021: Echo Hindle-Yang, Founder & CEO at MSQ Ventures, joined the “West-East Roundtable: Next Act Europe-China Collaborations” panel discussion at the 21st BioEquity Europe Conference.
Jan 28, 2021: 2021 Cross-Border Healthcare Innovation & Partnership Summit was successfully held virtually by MSQ Ventures and Bayhelix. The summit and the panel were well-received, and MSQ Ventures will continue to boost cross-border collaboration and communication in the biopharmaceutical industry.
Dec 18, 2020: 2nd Annual Bio Cross-border Investment & Partnership Summit 2020 was successfully held in Shanghai, together with CMG-SDIC Capital (State Development & Investment Corporation) and Pharnex. Over 70+ life science executives and investors joined our team in Shanghai, and 10+ western biotech executives presented virtually from their homes during the summit.
Dec 15, 2020: MSQ client ADC Therapeutics Formed Strategic JV with Overland Pharma to Expand ADC Drugs Development and commercialization in Greater China and Singapore. Overland Pharmaceuticals has invested $50 million in the Strategic JV Overland ADCT BioPharma, and Overland Pharmaceuticals will have a 51% stake and ADC Therapeutics a 49% stake.
Oct 28, 2020: MSQ client BioInvent International has successfully entered into a licensing agreement with CASI Pharmaceuticals for Greater China region. BioInvent will receive $12 million upfront and eligible to receive up to $83 million in milestone payments, plus tiered royalties. Congratulation to both sides on the deal!
Oct 2020: MSQ published Viewpoint “At the Crossroad - Bring Innovative Drugs Into China’s Biopharmaceutical Market” to address key concerns biopharmaceutical companies are facing to enter China
Mar 25, 2020: MSQ published Healthcare Newsletter 2020 - COVID-19 & Infectious Disease to express our opinions towards the recent global outbreak and share our insights with people who are affected
Mar 3, 2020: MSQ published Healthcare Newsletter 2020 - Equity Capital Market to express our opinions towards China Market
Jan 23, 2020: MSQ worked with WeWork to co-host the Chinese New Year Happy Hour, to welcome the Year of the Rat!
Nov 1, 2019: The MSQ Annual Scavenger Hunt